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CD8+ T cells are an essential component of an eﬀective host immune response to tumors and viral infections. Genetic
immunization is particularly suitable for inducing CTL responses, because the encoded proteins enter the MHC class I processing
pathway through either transgene expression or cross-presentation. In order to compare the eﬃciency and persistence of immune
response induced by genetic vaccines, BALB/c mice were immunized either twice intramuscularly with DNA plasmid expressing a
codon-optimized HIV-1 gp120 Envelope sequence together with murine GM-CSF sequence or with a single immunization using
an integrase defective lentiviral vector (IDLV) expressing the same proteins. Results strongly indicated that the schedule based on
IDLV vaccine was more eﬃcient in inducing speciﬁc immune response, as evaluated three months after the last immunization by
IFNγ ELISPOT in both splenocytes and bone marrow- (BM-) derived cells, chromium release assay in splenocytes, and antibody
detection in sera. In addition, IDLV immunization induced high frequency of polyfunctional CD8+ T cells able to simultaneously
produce IFNγ,T N F α,a n dI L 2 .
1.Introduction
The importance of CD8+ T cells in viral clearance has
been established in several viral models [1], including the
nonhuman primate model of AIDS, in which depletion of
CD8+ T cells resulted in the inability to clear infection
[2, 3]. Several other evidences demonstrated the importance
of the CD8+ T cell responses for controlling HIV infection.
Indeed, slow AIDS disease progression is associated with
functional CD8+ T cell responses, speciﬁc HLA class I alleles
are associated with slower progression of disease in HIV-
infected people, and CTL escape is a major force driving
HIV evolution (reviewed in [4, 5]). Based on these ﬁndings,
vaccines inducing strong and long-lived CD8+ T cells are
highly desirable. Genetic immunization using plasmid DNA
or viral vectors is particularly suitable for inducing CTL
responses,becausetheencodedproteinenterstheMHCclass
I processing pathway through either direct transgene expres-
sion or cross-presentation by resident antigen presenting
cells (APCs). Among viral vectors, lentiviral vectors (LVs)
have been shown to eﬃciently transduce non replicating
cells in vitro as well as in vivo and to be able to elicit
potent humoral and cellular responses (reviewed in [6]).
LV-transduced human DCs are able to present antigenic
peptides and prime transgene-speciﬁc T cells in vitro [7, 8].
It has been shown that LV-encoding HIV-1 polyepitopes
induce broad CTL responses in mice [9], and we reported
that a single intramuscular administration of HIV-based LV-
expressingviralantigenselicitsstrongcell-mediatedimmune
responses [10, 11]. Importantly, Beignon and colleagues2 Journal of Biomedicine and Biotechnology
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Figure 1: HIV-based transfer vectors plasmid used in this study. The internal CMV promoter drives the expression of the codon-optimized
HIVJR-FL gp120 Envelope protein and the murine GM-CSF (mGM-CSF). The packaging signal (Ψ), primer binding site (PBS), major splice
donor (SD) and acceptor (SA) sites, bovine Growth Hormone polyadenylation signal (bHGpA), central polypurine tract (cPPT), internal
ribosomal entry site from poliovirus (pIRES), and Woodchuck posttranscriptional regulatory element (WPRE) are indicated.
recently provided the ﬁrst evidence that an LV-expressing
simianimmunodeﬁciency virus-(SIV-)Gagprotein wasable
to induce control of viral replication in monkeys challenged
with high dose of SIV [12]. However, safety concerns relative
to the use of these vectors for delivery of therapeutic genes or
for a vaccine include insertional mutagenesis and/or vector
mobilization following viral infection. To minimize the risk
of insertional mutagenesis, integrase defective lentiviral vec-
tors (IDLV) have been engineered to present viral antigens
in a similar but safer manner [13, 14]. Several reports have
shown that HIV- or SIV-derived integrase defective viruses
as well as IDLV are transcriptionally active although at
lower levels than the integrated wild-type counterpart, while
producing extrachromosomal forms of viral DNA (E-DNA)
in the absence of noticeable amounts of integrated provirus
[14, 15].
We have recently demonstrated that a single immuniza-
tionwithanonintegratinglentiviralvectorcarryingacodon-
optimized HIV-1 gp120 Envelope protein in mice results in a
strong and sustained immune response characterized by the
presence of anti-gp120 antibodies, eﬀector-speciﬁc T cells
and generation of a speciﬁc T cell memory, without integra-
tion of the vector into the host genome [16]. Importantly,
several groups conﬁrmed the use of IDLV as an eﬀective
vaccine delivery strategy [17–19] ,a n dw ep r o v i d e de v i d e n c e
that SIV-based IDLV can be constructed and used as well
[20].
In this work we compared the ability to induce long-
lasting CD8+ T cell response in mice upon immunization
with DNA plasmid or IDLV expressing the HIV-1 gp120
Envelope protein. A detailed evaluation of CD8+ T cell
immune response was performed at three months after the
last immunization. Moreover, a comprehensive analysis of
the quality of CD8+ T cell response induced by IDLV is
reported.
2.MaterialsandMethods
2.1. Vectors Construction. A schematic depiction of the
lentiviral transfer vector plasmids used in this study is
shown in Figure 1. Details on vectors construction are
provided in [16]. Brieﬂy, the HIV-based transfer vector
plasmidpTY2-JRmZencodes theHIV-1JR-FL gp120 Envelope
protein sequence (HIV-Env) and the murine granulocyte
monocyte-colony stimulatory factor (mGM-CSF) from the
internal CMV promoter; the HIV-based transfer control
vector plasmid pTY2-EmptymZ encodes only the mGM-
CSF from the sequence for the poliovirus internal ribosomal
entry site (pIRES). The Integrase (IN) defective packaging
plasmid pcHelp/IN-, obtained from Dr. J. Reiser (Louisiana
State University Health Sciences Center, New Orleans, USA),
is necessary for production of the vector particles and
contains a D116N mutation in the IN genome, preventing
the functions characteristic of the IN protein [16]; plasmid
pMD G [21], obtained from Dr. D. Trono (University of
Lausanne, Switzerland), produces the vescicular stomatitis
virus envelope glycoprotein G (VSV G).
2.2. Production of Recombinant Vectors. The human epithe-
lium kidney 293T cell line was maintained in Dulbecco’s
Modiﬁed Eagles medium (Euroclone, Life Sciences Division,
Pero, Milan, Italy) supplemented with 10% fetal calf serum
(Euroclone, Life Sciences Division) and 100units/mL of
penicillin-streptomycin-glutamine (Gibco Invitrogen, Pais-
ley, UK). For production of recombinant IDLV expressing
HIV-Env (IDLV-JRmZ), cells were transiently transfected
using the calcium phosphate-based Profection Mammalian
Transfection System (Promega Corporation, Madison, WI,
USA) as previously described [16, 22] using a total of
24μg of plasmid DNA with a ratio of 4 : 3 : 1 (pTY2-
JRmZ:pcHelp/IN-:pMD G), thus producing the IDLV-
JRmZvaccinepreparation.Forproductionofcontrolrecom-
binant IDLV (IDLV-Empty), the pTY2-EmptymZ plasmid
was used in place of pTY2-JRmZ, thus producing the
IDLV-Empty vaccine preparation. After 48 hours, culture
supernatants were cleared from cellular debris and passed
through a 0.45μm pore size ﬁlter (Millipore Corporation,
Billerica,MA,USA).Filteredsupernatantswereconcentrated
by ultracentrifugation (Beckman Coulter, Inc., Fullerton,
CA, USA) for 2 hours at 27000rpm on a 20% sucrose
gradient (Sigma Chemicals, Co., St. Louis, MO, USA).
Finally, the viral pellets were resuspended in 1 × PBSJournal of Biomedicine and Biotechnology 3
a n ds t o r e da t−80◦C for further analyses. Viral titres were
normalised by the RT [23] and p24 ELISA assays (Innotest,
Innogenetics, Belgium).
2.3. Mice Immunization. BALB/c mice were kept in accor-
dance with the European Union guidelines and Italian
legislation. All protocols were approved by the authors’
Institutional Review Board. Four mice per group were
intramuscularly immunized (i) twice with plasmid pTY2-
JRmZ expressing HIV-Env and mGM-CSF (DNA-JRmZ),
(ii) twice with plasmid pTY2-EmptymZ expressing only
mGM-CSF (DNA-Empty); (iii) once with IDLV expressing
HIV-Env and mGM-CSF (IDLV-JRmZ) and (iv) once with
IDLV expressing only mGM-CSF (IDLV-Empty), Mice from
DNA groups were immunized intramuscularly with DNA
(80μg/mouse) on day 0 and after1 month were boosted with
the same dose of DNA. Mice from IDLV groups received a
single inoculum of 1 × 107 RT units of IDLV formulated in
0.2mL of PBS. Na¨ ıve mice were added as further control.
Three months after the immunization mice were sacriﬁced.
At sacriﬁce mice were ﬁrst bled orbitally under metaphane-
induced anesthesia, and sera were collected and kept at
−80◦C. Single cell suspension from spleen was prepared by
mechanical disruption and passage through cell streiners
(BD Falcon). BM-derived cells were obtained from tibiae by
syringe insertion into one end of the bone and ﬂushing with
RPMI medium.
2.4. IFN-γ ELISPOT Assay. The IFN-γ ELISPOT assay was
performed on splenocytes and BM-derived cells by using
reagents from Mabtech (Mabtech AB Gamla V¨ armd¨ ov,
Sweden) as described in [16]. The JR-9mer peptide con-
taining the H-2d restricted HIV-1 gp120 Envelope epitope
(IGPGRAFYT) (UFPeptides s.r.l., Ferrara, Italy) and the H-
2d restricted GFP-9mer peptide (HYLSTQSAL) (UFPeptides
s.r.l., Ferrara, Italy) were used at 5μg/ml as speciﬁc and
unrelated stimuli, respectively. Concanavalin A (SIGMA,
Chemical Co. St. Louis, MO, USA) was used as a positive
control.Speciﬁcsamples(speciﬁcpeptide-treatedwells)were
subtractedfromthevaluesobtainedintheunrelatedpeptide-
treated wells (background) and were scored positive when
were present a minimum of 50 spots per 106 cells and a fold
of 2 or higher compared to the unrelated peptide-treated
samples.
2.5. Antibodies and Intracellular Staining (ICS). Splenocytes
from single animals (four mice/group) were cultured with
the speciﬁc JR-9mer (5μg/mL) or the unrelated GFP-
9mer (5μg/mL) H-2d-restricted peptides in the presence
of anti-mouse CD28 mAb (clone 37.51) at 2μg/mL. PMA
(50ng/mL) in combination with Ionomicin (2μg/mL) was
used as positive control. After 1 hour from the stimulation,
10μg/ml of Brefeldin A was added to the cultures as a
protein transport inhibitor. After 6 hours of incubation, cells
were stained with PercP anti-mouse CD8a, or the isotype-
matched mAb. Then cells were permeabilized and stained
with PE-labeled anti-mouse IL2, APC-labeled IFNγ,a n dP E -
Cy7-labeled TNFα mAbs or their isotype-matched controls
in PBS-0.5% saponin and analyzed by ﬂow cytometry. All
monoclonal antibodies were from BD Pharmingen (San
Diego, CA, USA), and all chemicals were from Sigma
Chemicals, Co. (St. Louis, MO, USA). Acquisition and
analysis were performed using FACSCanto and FACS Diva
software (BD Biosciences, USA).
2.6. In Vitro Stimulation of Eﬀector Cells and 51Chromium
Release Assay. Stimulator splenocytes from na¨ ıve BALB/c
mice were pulsed for 1 hour with the Envelope-speciﬁc
JR-9mer H-2d-restricted peptide at 5μg/mL in serum-free
medium, irradiated with 3000 Rads on a 60Co source,
washed once, and then added to eﬀector splenocytes derived
from immunized mice, at an eﬀector : stimulator ratio of
10 : 1. After 4 days of culture, eﬀector cells were tested in
51Chromiumreleaseassaysfortheanalysisofantigen-speciﬁc
T cells, as described in [16].
2.7. Antibody Detection. Speciﬁc antibody titres against
HIV-gp120 Envelope protein were measured by ELISA as
previouslydescribed[16].Brieﬂy,ninety-sixﬂat-bottomwell
microplates (Nunc GmbH & Co. KG, Wiesbaden, Germany)
were coated with 100ng/well of HIV-1SF162 gp120 (NIH
Repository Reagents, Bethesda, MD, USA) in carbonate
buﬀer (Sigma Chemical Co. St. Louis, MO, USA). After
overnight incubation at 4◦C, wells were washed and mice
sera were serially diluted and added to the plates. Goat
anti mouse IgG peroxidase-conjugated secondary antibody
(Sigma Chemical Co. St. Louis, MO, USA) was added to
each well and incubated for an additional 90min at 37◦C.
Antigen-bound antibodies were revealed by the addition of
ABTS solution (Roche Diagnostic S.p.a, MI, Italy). Cut-oﬀ
values were established for each plate and in each run and
were based on the average serum samples plus 2 standard
deviations (SD) from 4 naive mice ( value). Serum samples
with  values higher than the cut-oﬀ value were considered
to be positive by ELISA for HIV-Env antibodies.
2.8. Statistical Analysis. Statistical analyses were performed
by nonparametric Mann-Whitney U test. All P-values were
two tailed and considered signiﬁcant if less than .05. All
analyses were performed using SPSS for Windows version
13.0 (SPSS Inc., Chicago Illinois US).
3. Results and Discussion
3.1. IDLV Is More Eﬃc i e n tt h a nD N Ai nI n d u c i n gA n t i g e n -
Speciﬁc IFNγ Producing CD8+ T Cells in Splenocytes and
BM-Derived Cells. The presence and the persistence of the
immune response were evaluated at 90 days from the last
immunization in mice (4 mice/group) inoculated twice with
plasmid DNA (DNA-JRmZ) or once with IDLV (IDLV-
JRmZ), both expressing codon-optimized HIV-1JR-FL gp120
EnvelopeandmurineGM-CSF.Controlarms(4mice/group)
included mice inoculated twice with plasmid DNA (DNA-
Empty) or once with IDLV (IDLV-Empty), both expressing
o n l ym u r i n eG M - C S F ,a sw e l la sn a ¨ ıve mice. As determined4 Journal of Biomedicine and Biotechnology
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Figure 2: T cell responses measured on splenocytes (a) and BM-
derived cells (b) at 90 days from immunizations. Results from one
representative experiment out of three independent experiments
are shown. IFN-γ ELISPOT was performed on cells stimulated
overnight with either H-2d restricted speciﬁc Envelope JR-9mer
peptide or H-2d restricted unrelated GFP-9mer peptide. IFN-γ
producing T cells are expressed as SFC/106 cells after background
subtraction (see Section 2). The error bars indicate the standard
deviation among four mice of the same group, and P-values are
indicated for intergroup comparisons.
by IFNγ ELISPOT on ex vivo splenocytes, IDLV-JRmZ-
immunizedmiceshowedahighlevelofantigenspeciﬁcIFNγ
producing T cells, with spot forming cells (SFC)/106 ranging
from 473 to 960, with an average value of 662 (Figure 2(a)).
The number of antigen-speciﬁc IFNγ producing T cells was
lower in mice immunized twice with DNA-JRmZ (SFC/106
cells ranging from 35 to 345, with an average value of 150)
(Figure 2(a)). The diﬀerence between groups was statistically
signiﬁcant (P<. 01).
Recently, it has been proposed that the bone marrow
(BM) is a crucial organ for traﬃcking of mature T cells and
contributes greatly to long-term cytotoxic memory as well as
to homeostatic regulation of peripheral CD8 T cell numbers
[24]. To evaluate if the vaccinations induced a memory
responsedetectablethreemonthsafterthelastimmunization
in BM, IFNγ ELISPOT was performed on BM-derived
cells. IDLV-JRmZ-treated mice showed detectable levels
of antigen-speciﬁc IFNγ producing cells localized in BM
(SFC/106 cells ranged from 107 to 337, with an average value
of 212) (Figure 2(b)). This is particularly striking in light of
the fact that only 2%-3% of the cells derived from BM were
CD8+. Conversely, antigen-speciﬁc IFNγ producing cells
were not detected in BM of DNA-JRmZ-immunized mice
(Figure 2(b)).Thediﬀerencebetweengroupswasstatistically
signiﬁcant (P<. 05).
Overall, these results indicate that a single injection of
IDLV-JRmZ is more eﬃcient than two immunizations with
DNA-JRmZ in inducing antigen-speciﬁc IFNγ producing
CD8+ T cells. In addition, the presence of immune response
in spleen and BM at three months from the single immu-
nization indicates that IDLV is able to induce a long-lasting
immunity.
3.2. IDLV Immunization Induces Functional Cytotoxic T Lym-
phocytes (CTLs). To analyze the eﬀective ability of antigen-
speciﬁcCD8+Tcellsinducedbythevaccinesinkillingtarget
cells, a chromium release assay was performed. This was
deemed necessary since production of IFNγ by CD8+ T cells
doesnotdirectlyimplytheirabilitytokilltargetcells,asithas
been already demonstrated for instance in the case of HIV-
infected patients, where the ability to produce cytokines was
not associated with the cytolytic function [25].
The presence of CTL was investigated on splenocytes
derived from immunized mice, stimulated in vitro with irra-
diated na¨ ıve splenocytes pulsed with the speciﬁc Envelope
JR-9mer peptide. Speciﬁc lysis of target cells was evident
in mice immunized once with IDLV-JRmZ (up to 30% of
speciﬁc lysis at E : T ratio of 40 : 1), whereas splenocytes
from mice immunized twice with DNA-JRmZ did not show
C T La c t i v i t ya ta n yE : Tr a t i ot e s t e d( Figure 3(a)). No
speciﬁc responses were detected in the mice immunized with
DNA-Empty, and IDLV-Empty and in na¨ ıve mice, used as
negative controls (Figure 3(a)).
These data clearly indicated that only the immunization
with IDLV-JRmZ was able to induce antigen-speciﬁc CD8+
T cells competent for both cytokine production and cytolytic
eﬀector function.
3.3. IDLV Immunization Induces Antigen-Speciﬁc Antibody
Response. An eﬃcient antibody response was not expected
upon immunization with IDLV-JRmZ, due to the reported
low protein expression from the non-integrated viral E-DNA
[14]. Indeed, mice immunized with IDLV-JRmZ displayed
low but detectable anti-Env IgG titers (geometric median
titer 400) whereas mice immunized with DNA-JRmZ did not
generate any antibody response (Figure 3(b)). Results were
comparabletothoseobtainedinapreviousexperimentusing
the same IDLV [16]. The presence of a speciﬁc antibody
responseinthecaseofIDLVisattractive,consideringapossi-
bleprime-boostvaccineprotocol,usingIDLVasprimingand
the corresponding protein for boosting humoral response.
3.4. IDLV Immunization Induces Polyfunctional CD8+ T
Cells. Several authors have recently conﬁrmed the eﬃcacy
of IDLV vaccination in animal models [17–20, 26]. Due
to its safety proﬁle and immunization eﬃciency, there is,
therefore, an increasing interest in the use of this vector for
vaccine purposes in diﬀerent disease models, including viral
infections and tumors [27].
To further characterize the CD8+ T cell response, we
carried out a more detailed analysis of the quality of immuneJournal of Biomedicine and Biotechnology 5
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Figure 3: (a) Anti-Env speciﬁc CTL activity in mice immunized
with IDLV-JRmZ, IDLV-Empty, DNA-JRmZ, and DNA-Empty or
in naive mice (four mice/group). Results from one representative
experiment out of three independent experiments are shown.
51Cr-release assay was performed after 4 days in vitro culture, as
described in Section 2. The percentage of speciﬁc lysis is shown at
three diﬀerent E : T ratios: 40 : 1, 20 : 1, and 10 : 1. (b) Anti-HIV-
Env IgG antibodies measured by ELISA in sera of mice at 90 days
after immunization. Sera samples from the immunized mice were
analyzed separately. Line represents the geometric median value in
the IDLV-JRmZ group.
response induced by IDLV immunization. In particular, an
intracellularstaining(ICS)forIFNγ,TNFα,andIL2wasper -
formed in splenocytes of mice immunized with IDLV-JRmZ
and DNA-JRmZ and control mice. As shown in Figure 4(a),
CD8+ T splenocytes from both IDLV-JRmZ- and DNA-
JRmZ-immunized animals produced all three cytokines,
when cultured in vitro in the presence of the Envelope-
speciﬁc peptide. Importantly, IDLV-JRmZ-immunized mice
showed a statistically signiﬁcant higher percentage of CD8+
T cells producing IFNγ,T N F α,o rI L 2w h e nc o m p a r e dt o
DNA-JRmZ-vaccinated mice (P<. 05). Splenocytes from
na¨ ıve mice or from mice immunized with IDLV-Empty and
DNA-Empty did not show any signiﬁcant production of
cytokines.
To evaluate the presence of polyfunctional antigen-
speciﬁc CD8+ T cells, IFNγ producing CD8+ T cells were
gated and evaluated for production of TNFα and IL2. In
Figure 4(b) a representative analysis shows that the majority
of the IFNγ-producing CD8+ T cells from the IDLV-JRmZ
and DNA-JRmZ-immunized mice also produce TNFα and
IL2 (86% and 75%, respectively). These results indicate that
while both vaccinations qualitatively induced similar CD8+
T cell responses, immunization with IDLV induced a higher
number of polyfunctional antigen-speciﬁc T cells.
It has been suggested that the presence of such polyfunc-
tional cells correlates with a better prognosis in chronically
infected patient with CMV and EBV and in long-term non
progressor HIV-1-infected patients [28]. Therefore, the use
of IDLV-based vaccines, capable of inducing high levels of
polyfunctional CD8+ T cells, after a single immunization
represents a very attractive and desirable vaccine strategy.
4. Conclusions
Usually, the immune response induced by DNA injection is
weak. To circumvent this limitation in our study we used
a single intramuscular injection of IDLV-delivered Envelope
sequence in the mouse model which performed better than
two immunizations with naked DNA plasmid delivering the
same antigen. The mGM-CSF coding sequence was included
in both immunization protocols in the eﬀort to improve
immune response. Nevertheless, two immunizations with
DNA were not suﬃcient to induce an immune response
comparable to that induced by a single immunization with
IDLV expressing the same antigen. The diﬀerence in the
ability to induce immune response could be partly explained
by considering the advantage of the vector, in terms of
uptake and stability in vivo, compared with naked DNA.
The delivery of DNA through electroporation (EP) might
overcome these limitations, even if safety-related issues of
EP, in the case of administration of vaccines to humans,
need to be better investigated [29]. However, the aim of
our study was to provide evidence of the potency of IDLV
as a vaccine and to characterize the CD8+ T cell response
induced by this novel, safe, and promising vector for genetic
immunization.
The eﬃciency of IDLV observed in our and in other
models [27], in terms of quantity, persistence, and quality
of CD8+ T cell response, could be reasonably considered
an excellent beginning for future exploitation of this vector
for developing vaccine strategies aimed at inducing CD8+ T
cell responses. The possibility to use IDLV in heterologous
prime-boost protocols as well as in mucosal vaccine, in
order to improve immune response at both systemic and
mucosal sites, should be further investigated. Finally, to
have the proof of concept that this vector could represent a
novel and eﬀective delivery system for vaccine strategies in
humans, experiments in the nonhuman primate model of
AIDS should be performed by evaluating the strength of the6 Journal of Biomedicine and Biotechnology
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Figure 4: Analysis of cytokine production by intracellular staining (ICS). Results from one representative experiment out of three
independent experiments are shown. (a) Splenocytes from mice immunized with IDLV-JRmZ, DNA-JRmZ, IDLV-Empty, and DNA-Empty
or from na¨ ıve mice were cultured in vitro with Envelope-speciﬁc JR-9mer peptide and then stained for IFNγ,T N F α, and IL2. Error bars
indicate the standard deviation among four mice of the same group. Data are expressed as percentage of single cytokine-producing T cells
by gating the CD8+ T cell population. (b) IDLV-JRmZ vaccination induced high frequency of polyfunctional antigen-speciﬁc CD8+ T cells
able to simultaneously produce IFNγ, IL2, and TNFα. A representative experiment is shown. The analysis was performed on CD8+ T cells
from the mice immunized with IDLV-JRmZ (upper panels) or DNA-JRmZ (lower panels). CD8+/IFNγ-producing cells were gated and
analyzed for the production of both TNFα and IL2. Within the dot plots the percentages of single (IFNγ) and double (TNFα and IL2)
cytokine-producing CD8+ T cells are indicated. FSC: forward scatter.
immune response induced in terms of both frequency and
quality of viral-speciﬁc T cells and the ability in controlling
the viral challenge.
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